Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
Antisense approaches to cancer gene therapy.
Cancer Gene Ther. 1995 Mar;2(1):47-59. Unique Identifier : AIDSLINE MED/95346705 Mercola D; Cohen JS; San Diego Regional Cancer Center, CA 92121, USA.
Abstract:
Recent advances in the use of oligodeoxynucleotide and plasmid-derived RNA as antisense agents of special relevance to cancer gene therapy are summarized with emphasis on agents and systems which have lead to clinical trials and/or regression of established tumors in animal model systems. Transformed cell lines bearing plasmids and viruses designed for the transcription of antisense RNA have the advantage that they can be characterized thoroughly and the effects of antisense RNA on target gene expression and phenotype can be studied easily in vivo. Promising results make the considerable efforts of applying oligodeoxynucleotides in whole animals and in clinical trials more plausible. Conversely, oligodeoxynucleotide experiments which yield promising results in tissue culture can be generalized to the in vivo setting by development of clones of cells bearing plasmid-derived antisense RNA against the same target. Several examples of the concordant results for oligodeoxynucleotide and plasmid-derived antisense RNA against the same target are considered. The importance of examination of antisense effects in syngeneic and immunocompetent hosts is illustrated by studies of insulin-like growth factor and insulin-like growth factor receptor where tumor regression and protection against tumor formation have been observed for particular cell types in defined settings.
Keywords: Acquired Immunodeficiency Syndrome/GENETICS/THERAPY Animal Base Sequence Cell Line Clinical Trials Forecasting Gene Expression Gene Therapy/*METHODS Genetic Vectors Growth Substances/GENETICS Human Immunocompetence Mice Models, Biological Molecular Sequence Data Neoplasms/GENETICS/*THERAPY Neoplasms, Experimental/GENETICS/THERAPY Oligonucleotides, Antisense/ADMINISTRATION & DOSAGE/GENETICS/ PHARMACOLOGY/*THERAPEUTIC USE Oncogenes Rats RNA, Catalytic/THERAPEUTIC USE RNA, Messenger/ANTAGONISTS & INHIB RNA, Neoplasm/ANTAGONISTS & INHIB Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Transcription, Genetic/DRUG EFFECTS JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
